The company also plans to continue the development of its kt-3000 series through collaborations and partnerships with biotech and pharma companies. Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics, expressed gratitude to the investors and highlighted the company's recent data which demonstrates that the Deep Docking AI platform has delivered on its objective, generating a focused shortlist of potential best-in-class PARP-1 inhibitor candidates capable of crossing the blood-brain barrier. The next step is validating these promising candidates using their wet-lab infrastructure at the University of British Columbia.
Key takeaways:
- Rakovina Therapeutics Inc. has announced a non-brokered private placement offering of up to $1.25 million.
- The company has received initial commitments totaling over $800,000 from strategic investors in connection with the Offering.
- The Offering is structured as units priced at $0.06 each, with each unit consisting of one common share and one warrant to purchase a common share.
- The proceeds will be used to continue the discovery and advancement of novel cancer treatments by leveraging collaborations with two proprietary Artificial Intelligence (AI) platforms: the Deep Docking™ AI platform and the Variational AI Enki™ Platform.